Immunome (IMNM) Piper Sandler 36th Annual Healthcare Conference summary

Strategic growth and acquisitions

• Expanded team from a single Seattle employee to over 100, integrating experienced executives from Seagen.

• Acquired AL102, a late-stage small molecule for desmoid tumors, and ROR1 ADC from Zentalis, enhancing the pipeline.

• Added a discovery platform with over 25-30 targets and acquired 25 antibodies from Atreca to fuel future ADC development.

• Focused on building a leading ADC company with a strong emphasis on discovery and organic pipeline growth.

AL102 for desmoid tumors

• AL102 showed a 64% response rate in phase II, outperforming the 41% seen with the current standard, Ogsiveo.

• Efficacy is the main differentiator, with similar toxicity profiles to Ogsiveo; patients remain on therapy for extended periods.

• The U.S. market size may exceed previous estimates, potentially reaching up to 10,000 patients as awareness and diagnosis improve.

• Phase III RINGSIDE trial is ongoing, with data expected in the second half of 2025; primary endpoint is PFS, but response rate and quality-of-life measures are key.

• Commercialization groundwork is underway, with a head of commercial hired and a focus on a targeted, tractable launch.

ROR1 ADC and pipeline strategy

• ROR1 ADC leverages a proprietary TOPO1 payload (HC-74), designed for both solid and liquid tumors, with improved properties over existing payloads.

• IND filing for ROR1 ADC is planned for Q1 2025, with rapid initiation of phase I dose escalation in both hematologic and solid tumors.

• The TOPO1 payload allows higher dosing and may overcome limitations seen in prior ROR1 ADCs, such as Merck’s VelosBio asset.

• Pipeline expansion is driven by a focus on novel targets, leveraging the Atreca antibody acquisition and in-house validation capabilities.

• Disclosure of new targets will be cautious to maintain competitive advantage, but candidate data may be shared sooner.